The honest UK respiratory medicine answer: vape has real but mostly mild short-term effects on the lungs, with long-term effects still being researched. Per a 2021 systematic review of 8 studies on vape and lung function published in npj Primary Care Respiratory Medicine: “vaping increases airway resistance but does not appear to impact forced expiratory volume in one second (FEV-1), forced vital capacity (FVC), or FEV-1/FVC ratio. However, given the limited size and follow-up duration of these studies, larger, long-term studies are required to further determine the effects of e-cigarettes on lung function.” UK Asthma and Lung UK position: vape less harmful than smoking but not risk-free for lungs.

Documented short-term lung effects from peer-reviewed research. Airway irritation: PG (propylene glycol) is hygroscopic, dries airway surfaces, causes throat and bronchial irritation. Common in new vapers. Cough: especially in new vapers, often transient as airways adjust. Increased airway resistance: small but measurable effect, mostly preserved FEV1 and FVC. Acute bronchoconstriction: documented in some studies (guinea pig research, some human studies). Reduced lung function in animal models (rats, guinea pigs): impaired ventilation, decreased lung air volume, denser lung tissue. Mucociliary clearance disruption: may slightly impair the lung’s natural cleaning mechanism.

EVALI (e-cigarette or vaping product use-associated lung injury) is a serious lung injury syndrome that peaked in the 2019-2020 US outbreak with ~2,800 hospitalisations and 60+ deaths. Investigations identified vitamin E acetate (used as thickening agent in illegal THC vape liquids) as the primary cause – found in lung fluid of nearly all EVALI patients. Per a landmark study in The New England Journal of Medicine: vitamin E acetate is banned in UK regulated nicotine vapes. UK EVALI risk is therefore very low but non-zero. Symptoms include shortness of breath, pain when breathing, cough, fever, gastrointestinal symptoms, fatigue. Most cases recover with treatment (oxygen, steroids), some require hospitalisation, very rare deaths. UK Health Security Agency monitors UK cases. UK nicotine vapers purchasing from licensed UK retailers face minimal EVALI risk; UK illegal THC vape products carry higher risk.

What actually happens in lung tissue when you vape

Pulmonologists describe vape lung effects in three layers. Layer 1: airway surface (trachea, large bronchi). PG and VG (vegetable glycerin) are humectants that absorb water from the airway mucosa. Acute effect: dry mucosa, decreased mucus production, slightly less effective mucociliary clearance. Symptoms: dry mouth, throat irritation, cough. Mostly reversible on cessation. Layer 2: small airways (bronchioles). Vape aerosol particles are typically 0.3-2 micrometers in size – small enough to reach the small airways. Effects: mild inflammatory response, slight increase in airway resistance, some studies show acute bronchoconstriction. Mucosal changes resemble those seen in early COPD but at much lower severity than smoking. Layer 3: alveoli (gas exchange surfaces). The deepest part of the lung. Vape aerosol reaches alveoli but in much smaller quantities than cigarette smoke. Some animal studies show alveolar wall thickening, fluid accumulation, immune cell infiltration. EVALI specifically causes severe alveolar damage (lipoid pneumonia pattern). Long-term effects on alveolar tissue in regular vapers are not yet definitively known. Per Johns Hopkins Dr Broderick: “we think that some of the vaporized elements of the oil are getting deep down into the lungs and causing an inflammatory response.” Per American Lung Association: “biologically, damage is happening. The inflammation is happening. And the concern is, we’re creating the conditions that will lead to those diseases later.” UK context: regulated UK nicotine vape avoids the worst additives (vitamin E acetate banned), substantially limiting lung injury risk.

Vape vs smoking: dramatic lung harm comparison

Smoking and vape both deliver substances to the lungs but the chemistry is profoundly different. Smoking: combustion at ~900°C produces tar (sticky carcinogenic residue that coats airways and alveoli), carbon monoxide (binds haemoglobin reducing oxygen delivery), thousands of chemical compounds via pyrolysis. Tar accumulates in airways and triggers chronic inflammation. Carbon monoxide damages cardiovascular and respiratory function. Polycyclic aromatic hydrocarbons cause DNA damage leading to lung cancer. Over 20-30 years of smoking, these effects cause COPD (chronic obstructive pulmonary disease), emphysema, chronic bronchitis, lung cancer in 1 in 6 long-term smokers. Vape: heating at ~150-250°C produces vapour with far fewer chemicals. Tar absent. Carbon monoxide absent. Most volatile organic compounds dramatically reduced. King’s College London 2022 review: vapers who completely switched show “significantly lower levels in vapers” of major smoking-related lung toxicants. The 2022 Cochrane review of vape biomarkers found vapers had dramatically reduced exposure to carbonyl compounds, volatile organic compounds and tobacco-specific nitrosamines compared with continued smokers. UK research initiatives are tracking long-term vape cohort outcomes, with major data expected through the 2030s. UK Asthma + Lung UK: for current smokers with respiratory disease, switching to vape substantially reduces ongoing lung damage. For never-smokers: vape adds small but non-zero respiratory risk for no benefit.

Lung symptoms in UK vapers: what to watch for

Most UK vapers experience some mild respiratory effects. Common, usually benign symptoms: occasional cough (especially morning), dry throat, mild bronchospasm during/after vape sessions, increased phlegm production (paradoxically may also occur as airways clear smoking damage). These are normal and typically improve over time or with adjustments (lower PG e-liquid, lower nicotine, slower puffs, more hydration). Warning symptoms requiring medical attention: persistent cough lasting weeks, especially productive of blood; chest pain with breathing; significant shortness of breath at rest or with mild exertion; recurrent chest infections (pneumonia, bronchitis); fevers and chills without other explanation; unexplained weight loss; persistent wheezing. UK NHS pathway: GP appointment for any of these symptoms. Mention vape and smoking history honestly. GP may refer for chest X-ray, spirometry (lung function test), or specialist respiratory assessment. Asthma + Lung UK Helpline: 0300 222 5800 for advice. EVALI symptoms specifically: shortness of breath PLUS cough PLUS gastrointestinal symptoms (nausea, vomiting, diarrhoea) PLUS fever – this combination should prompt urgent medical attention. UK A+E (emergency department) appropriate for severe respiratory distress. For most UK vapers, mild symptoms resolve with product or technique adjustments; persistent or severe symptoms warrant medical assessment. Annual chest review for long-term heavy vapers is reasonable per Dr Broderick (Johns Hopkins) recommendation.

For UK adults vaping, the five-point framework below reflects respiratory medicine guidance.

For UK adults with existing respiratory disease (asthma, COPD, bronchitis), discuss vape use with your respiratory specialist or GP. For most patients with mild asthma, vape effects are manageable. For severe respiratory disease, vape may not be advisable. UK Asthma + Lung UK Helpline (0300 222 5800) provides free advice. For current smokers with respiratory disease, NHS guidance is that switching to vape substantially reduces ongoing lung damage. Our Omagh and Strabane teams stock TPD-compliant products from registered UK suppliers and can advise on lower-PG options for vapers with airway sensitivity.